标题
Current status in the discovery of dual BET/HDAC inhibitors
作者
关键词
BET, HDAC, Inhibitors
出版物
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume -, Issue -, Pages 127829
出版商
Elsevier BV
发表日期
2021-03-06
DOI
10.1016/j.bmcl.2021.127829
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
- (2020) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells
- (2020) Stephanie Laszig et al. CANCER LETTERS
- Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
- (2020) Dailin Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells
- (2020) Zhaoping Pan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
- (2020) Tingting Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
- (2020) Songwei Huan et al. Cancer Management and Research
- Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
- (2019) Gloria Manzotti et al. Cancers
- Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
- (2019) Andrew E. Shouksmith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
- (2019) Shiyao Sui et al. Cell Death & Disease
- BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
- (2019) Shilei Liu et al. CANCER SCIENCE
- Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
- (2019) Laura M. Tsujikawa et al. Clinical Epigenetics
- Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells
- (2019) María G. Cortiguera et al. Scientific Reports
- Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells
- (2018) Julius C. Enßle et al. CANCER LETTERS
- Dual or multi-targeting inhibitors: The next generation anticancer agents
- (2018) Nulgumnalli Manjunathaiah Raghavendra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
- (2018) Jie Zang et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
- (2018) Sa Rang Kim et al. Oncotarget
- Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
- (2018) Alexander S. Hölscher et al. Clinical Epigenetics
- Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy
- (2018) Alexander Badamchi-Zadeh et al. JOURNAL OF IMMUNOLOGY
- HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies
- (2018) Isabelle J. Marié et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy
- (2018) Yepeng Luan et al. JOURNAL OF MEDICINAL CHEMISTRY
- NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells
- (2018) Kotaro Hishiki et al. LEUKEMIA RESEARCH
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma
- (2018) Lei Zhao et al. NEOPLASIA
- Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents
- (2018) Gaoliang Cheng et al. BIOORGANIC CHEMISTRY
- Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs
- (2017) Jieni Xu et al. JOURNAL OF DRUG TARGETING
- Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups
- (2017) Viktoria Krieger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
- (2017) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines
- (2017) Katharina Stenzel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Bromodomain-Containing Protein 4
- (2017) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives
- (2017) Gebremedhin S. Hailu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
- (2017) Lianbin Yao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner
- (2017) Vivek Kumar Mishra et al. NUCLEIC ACIDS RESEARCH
- Selective BET bromodomain inhibition as an antifungal therapeutic strategy
- (2017) Flore Mietton et al. Nature Communications
- Combination therapy in combating cancer
- (2017) Reza Bayat Mokhtari et al. Oncotarget
- Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors
- (2016) Zhimin Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2
- (2015) V. Sancisi et al. CANCER RESEARCH
- Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
- (2015) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- (2015) Gabor Borbely et al. Oncotarget
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
- (2014) Stephen J. Atkinson et al. MedChemComm
- Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment
- (2013) Konstantinos A Papavassiliou et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
- (2013) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade
- (2013) Y J Kim et al. ONCOGENE
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation